Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36970
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grigoriadis G. | en |
dc.contributor.author | Fedele P.L. | en |
dc.contributor.author | Chee A. | en |
dc.contributor.author | Low M.S. | en |
dc.contributor.author | Vilcassim S. | en |
dc.contributor.author | Gregory G.P. | en |
dc.contributor.author | Gilbertson M. | en |
dc.contributor.author | Ratnasingam S. | en |
dc.date.accessioned | 2021-05-14T12:33:32Z | en |
dc.date.available | 2021-05-14T12:33:32Z | en |
dc.date.copyright | 2018 | en |
dc.date.created | 20180831 | en |
dc.date.issued | 2018-08-31 | en |
dc.identifier.citation | British Journal of Haematology. 182 (5) (pp 739-741), 2018. Date of Publication: September 2018. | en |
dc.identifier.issn | 0007-1048 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/36970 | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing Ltd | en |
dc.relation.ispartof | British Journal of Haematology | en |
dc.title | Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. | en |
dc.type | Letter | en |
dc.type.studyortrial | Opinion, perspective or news | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bjh.14871 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.orcid | Chee, Adrian; ORCID: http://orcid.org/0000-0001-6602-6447 | en |
dc.identifier.pubmedid | 28857117 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28857117] | en |
dc.identifier.source | 618120870 | en |
dc.identifier.institution | (Chee, Low, Vilcassim, Gregory, Gilbertson, Ratnasingam, Grigoriadis, Fedele) Monash Haematology, Monash Health, Clayton, Australia (Low, Fedele) Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (Vilcassim, Gregory, Grigoriadis) School of Clinical Sciences at Monash Health, Monash University, Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | bortezomib multiple myeloma proteasome inhibitors | en |
dc.identifier.authoremail | Fedele P.L.; pasquale.fedele@monashhealth.org | en |
dc.description.grant | Organization: *Janssen Pharmaceuticals* Organization No: 100008897 Country: United States Organization: *Leukaemia Foundation* Organization No: 501100000926 Country: Australia Organization: (MU) *Monash University* Organization No: 501100001779 Country: Australia Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Letter | - |
crisitem.author.dept | Haematology | - |
crisitem.author.dept | Haematology | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.